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Abstract
Channelopathy constitutes significant proportion of SCD worldwide (around 
10% or 370,000 deaths annually). It was creating a mysterious group of diseases 
until the second half of the last century when Anton Jervell and Fred Lange-Nielsen 
described Jervell Lange-Nielsen syndrome in 1957. It was late until 1995 where 
genetic characterization commenced. Later on, the massive genetic information 
with the discovery of genetic heterogeneity and allelic het¬erogeneity was a major 
victory in the field. The basic sciences in cellular electrophysiology and genetics 
complemented by meticulous clinical detection and the different clinical trials in 
the field opened a new era of wide therapeutic choices for clinicians. The knowledge 
obtained from the different experimental platforms especially the induced pluripo-
tent stem cells is promising. The revolutionary move in SCD and channelopathies 
is described where correlation between the arrhythmogenesis and fluctuation in 
SGMA is established and must be investigated. The observation of the arrhythmo-
genicity of SGMA fluctuation and its effect on HRV together with the differential 
effect of certain sympathovagal tones (more sympathetic innervation is favoring 
VT/VF in LQTS1, LQTS2 and SQTS but not BrS or ERS) are all future directions 
to optimize our preventive, diagnostic as well as therapeutic options of SCD and 
channelopathy in humans.
Keywords: arrhythmia, BrS: Brugada syndrome, CC: cardiac coherence, 
catecholaminergic polymorphic ventricular tachycardia, ERS: Early repolarization 
syndrome, heart rate variability, LQTS: Long QT syndrome, progressive cardiac 
conduction disease, sudden cardiac death, Schumann resonance, solar geomagnetic 
activity, SNP, SQTS
1. Introduction
One of the most devastating life moments that may impact the whole life of 
persons, families and societies is the sudden death experience of a close relative 
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or a beloved one. The whole medical provision is dedicated to prevent or delay 
death while maintaining good quality of life (QOL). For this reason, sudden loss 
of human life is creating the most serious challenge for medical professionals and 
decision makers. Sudden cardiac death (SCD) is defined as death occurring unex-
pectedly in the first hour after symptoms commence. In the United States, around 
300,000 deaths occur every year because of SCD. It is conspicuous that this huge 
loss in the world communities is creating a major social impact. This impact is 
undoubtedly more destructive with the loss of a young member of the family. Sadly, 
life-threatening arrhythmias and sudden cardiac death can be the first presenting 
symptom. Scientists and clinicians were racing in the last two decades in a unique 
complementary scientific effort to reconcile the rapidly growing body of knowledge 
of the molecular mechanisms and clinical correlates of SCD. In this chapter, we will 
discuss the available risk stratification for channelopathies and detailed management 
steps with focus on the different trials for pharmaceutical approach of the different 
channelopathies. The electrical therapy in the form of ICD is a critical management 
step but will be prioritized according to channelopathy type and clinical settings. 
Future speculations of fatal ventricular rhythms are going to be discussed with 
special reference to solar and geomagnetic activity fluctuation and heart rate vari-
ability (HRV) correlations to SCD and the up to the moment knowledge in its impact 
on channelopathies.
2. Management of ventricular arrhythmias in suspected channelopathies
2.1 The long QT syndromes’ risk stratification and management plan
The yield of genetic mutations in LQTS is better than in other channelopa-
thies but still did not exceed 50%. The cutoff numbers for QTc interval before 
labeling it long is 480 and 470 ms in post pubertal women and men, respectively. 
In the 12 leads ECG, manual measurement from limb lead 2 or chest lead V5 
using Bazzet’s formula (QTc = QT/√RR) is a must. Moss and Schwartz devel-
oped a reliable scoring system for better risk stratification of LQTS individuals 
(Table 1) [1, 2]. Goldenburg criteria for risk stratification in long QT are also 
useful to add in clinical practice (Table 2) [3]. There must be no medications 
affecting ECG.
Schwartz score is more commonly used. The Schwartz score was proposed in 
1993 and revised in 2011 by Schwartz and Crotti [4]. Schwartz Moss scoring system 
comprises clinical, electrocardiographic as well as familial historical data. It is 
designed for use for the index case but not others. It was found to have high correla-
tion to positive genetic testing with 75% likelihood if the score is more than 4 points. 
It is not of use for a family member with long QT interval but with no symptoms [5]. 
T-wave abnormalities are important indicators for electrical instability. The score 
will count 1 point for positive T-wave alternans in the TWA test and another 1 point 
for notched T waves that are considered as poor prognostic sign. Poor prognostic 
factors with more likelihood for SCD are QTc more than 500 ms, LQTS symptoms, 
genotype of LQT2 or LQT3 and female gender. Male gender with LQT1 refers to 
lower risk group. The strongest indicator for SCD is the QTc interval [6]. Survival 
from cardiac arrest before age 7 or development of syncope before puberty carries 
worse overall prognosis [7]. Risk of recurrence is very high if syncope or cardiac 
arrest happens in the first year of life [8]. Genetic testing carries important prognos-
tic value as asymptomatic positive mutation individuals below 40 years of age carry 
10% higher risk of life-threatening arrhythmia if not treated [9]. Placebo controlled 
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randomized trials in LQTS management are lacking (except 2019 AHA editorial 
Published online 2019 May 29. doi: 10.1161/JAHA.119.012833, entitled “Energy 
Drinks: Another Cause of QT Prolongation?”) The assignment of placebo group in 
LQTS creates difficult ethical choices. Almost all present strategic plans in LQTS 
management were deduced from registries with beta blockers and cardioverter defi-
brillator (ICD) therapy [10]. Electrolytes disturbances correction like hypokalemia 
and hypomagnesaemia is a critical primary step in LQTS management. Magnesium 
sulfate intravenously proved to be safe and effective for acquired or congenital TdP 
management [11]. Beta blockers are the first line and the easiest therapeutic choice 
for both LQT1 and LQT2. In the current medical literature, there is controversy 
regarding the use of beta blockers in LQT3. For LQT1 and LQT2, propranolol and 
nadolol seem to be more effective than metoprolol [12]. Nadolol with its longer half 
life (twice a day) and sustained release propranolol seem to be attractive options. 
There are data suggesting that propranolol is more effective than atenolol [13]. 
Disease-specific favorable responses are suggested with nadolol providing the 
sole significant risk reducer in LQT2, while metoprolol, atenolol, propranolol and 
Risk factor Points
EKG findings
A: QTc
≥480 ms
460–479 ms
450–459 (men)
B: QTc fourth minute of recovery from exercise
Stress test ≥480 ms
C: TdP
D: T-wave alternans
E: Notched T-wave in 3 leads
F: Low heart rate for age (resting heart rate below the second percentile for age)
3
2
1
1
2
1
1
0.5
Clinical History
A: Syncope
With stress
Without stress
B: Congenital deafness
2
1
0.5
Family History
A: Family members with definite LQTS
B: Unexplained SCD at age < 30 years among immediate family members
1
0.5
Score ≤ 1 point: low probability of LQTS. 1.5–3 points: intermediate probability of LQTS. ≥3.5 points: high 
probability of LQTS.
Table 1. 
Updated Schwartz score: The same family member cannot be counted in A and B.
Very high risk (secondary prevention)
Postcardiopulmonary resuscitation
Spontaneous TdP
High risk (primary prevention)
QTc >500 ms
Prior syncope
Low risk
Qtc <500 ms and no prior syncope
Table 2. 
Goldenburg criteria for LQTS risk stratification.
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nadolol have similar risk reduction in LQT1 [14]. No significant scientific evidence 
is favoring selective beta blockers over the non-selective group [15]. It is always 
advised to keep beta blockers as adjunct treatment after ICD implants. The sym-
pathetic surge after delivery of a shock is always a risk for recurrence [16]. There 
are experimental data supporting the use of beta blockers in LQT3 [17] and others 
contradicting its use [18]. Analysis of 493 LQT3 patients derived from 9 registries 
supports the use of beta blockers [19]. There is in the horizon an early evidence 
suggesting significant therapeutic role of sodium channel blockers like ranolazine, 
mexiletine and flecainide in LQT3 treatment [20–22]. Mexiletine was proved also of 
being an effective therapeutic option in LQT3 as well as LQT1 and LQT2 [23].
Rarely, cautious use of mexiletine in LQT3 is needed as it may cause QT inter-
val prolongation [24]. Successful shortening of the QTc interval (565 ± 60 ms to 
461 ± 23 ms; P < 0.04) was achieved with flecainide. With its potent sodium block-
age properties, flecainide was able to normalize QTc in five patients with LQT3 
with DKPQ mutation [25]. Ranolazine, a late INa blocker, was seen to be effective to 
shorten the QT interval as well as suppress TdP as proved by experimental models 
of LQT3 [26]. Dose-dependent shortening of QT interval was achieved in human 
patients with DKPQ mutation of LQT3 using ranolazine [27]. What seems to be a 
therapeutic paradox is the benefit of adrenergic stimulation in cases with acquired 
LQTS and low heart rate with pauses. In the absence of concomitant gene muta-
tions, epinephrine and isoproterenol were found to be effective in acquired LQTS 
[28]. In addition, selective effect of β-adrenergic stimulation was reported in the 
different LQTSs. The effect was seen in canine models as induction of TdP in LQT1 
and LQT2 but suppression in LQT3 [29]. This concludes that therapeutic paradox is 
evident in LQTSs, as beta blockers are therapy of LQT1 and LQT2 but beta adren-
ergic stimulation is therapy for LQT3. Pause-dependent TdP in case of acquired or 
congenital LQT can be minimized using temporary pacing [30].
The implantation of an ICD is pivotal secondary prevention in LQTS and a 
reasonable primary prevention approach in selected cases [31]. Thoughtful ICD 
programming to prevent inappropriate shocks is important. In our practice, for 
LQTS secondary prevention, we do not incorporate tiered therapy for this type of 
patients but program the ICD to VF-only zone (detect rate, >220 beats per minute). 
ICD is indicated in the following conditions:
1. As secondary prevention after aborted cardiac arrest
2. Failure of optimal medical therapy to control events of cardiac arrest
3. Intolerance to primary pharmacotherapy (β-blockers)
4. Symptomatic patients with QTc of 500 ms or greater, especially women with 
LQT2
5. LQT3 genotype
Well-accepted treatment option in LQTS patients is left cardiac sympathetic 
denervation (LCSD). It is an exceptional therapeutic option that can be leaned 
on in selected cases like LQT1 and LQT2 patients with no proper response to 
beta blockers, intolerance to beta blockers, or after ICD implant with recurrent 
arrhythmias [32]. LCSD can be chosen as a primary treatment option or second-
ary, with what is described as excellent results in selected patients [33]. It seems 
that there are specific selection criteria to obtain optimal outcome of LCSD. More 
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than half of high-risk patients did not benefit from the procedure. Addition of 
right cardiac sympathetic denervation to LCSD might be of benefit in selected 
patients [34]. At all times, LCSD is not a replacement of the beta blockers and/or 
ICD therapy.
2.2 Brugada syndrome risk stratification and management plan
Any patient that survived a VF arrest or with syncope and an ECG consistent 
with spontaneous type I pattern should undergo permanent cardiac defibrillator. 
Other high-risk factors include male gender, atrial fibrillation or a fragmented 
QRS. There is no consensus on the use of electrophysiologic study to risk stratify 
patients. Importantly, the programmed electrical stimulation predictive value 
(PRELUDE) registry showed that the inability to induce arrhythmias does not 
correlate with a negative predictive value [35]. A family history of SCD and the 
presence of an SCN5A mutation have proven to be high risk predictors as well. 
Criteria to diagnose Brugada syndrome [36] in symptomatic patients are as fol-
lows: Type I ST segment elevation via drug challenge or spontaneously in at least 1 
right precordial lead (V1 or V2). In asymptomatic patients, the situation is little bit 
guarded. Constellation of strong and concealed electrocardiographic manifestation 
should be looked for. Attenuation of the ST segment during maximum exercise with 
subsequent coved ST segment elevation when rested is an important finding, in the 
setting of absent structural heart disease. StT wave alternans (TWA), development 
of spontaneous left bundle branch or PVCs are all relevant to alert to BrS diagnosis 
in the absence of symptoms. Other subtle electrical alerts are first-degree AV block 
and left axis deviation as well as fragmented QRS. In TWA test, late potentials are 
additional alerting alarm. During electrophysiological study, a ventricular effective 
refractory period less than 200 ms is alarming also. Other alerts are the fragmenta-
tion of QRS as well as the presence of atrial fibrillation.
BrS is well known to be triggered by febrile illness. This is why meticulous 
fever management should be carried out in Brugada patients and their families. 
Pharmaceutical agents inducing Brugada arrhythmias should be avoided. Physicians 
and public may refer to (www.brugadadrugs.org) for reliable information in this 
regard. Sympathovagal imbalance with dominant parasympathetic tone predisposes 
to ventricular arrhythmias in BrS patients. Isoproterenol intravenously is used with 
success to control VF storms in BrS patients [37]. In a limited study, quinidine was 
found to be of a role in asymptomatic individuals [38]. In case of frequent ICD 
shocks, quinidine can be used as adjunct treatment. Quinidine effectiveness was 
found to be 85% in a follow-up of up to 4 years with a dose of ≤600 mg per day 
[39]. An empirical quinidine registry for asymptomatic Brugada individuals recom-
mended doses of 600–900 mg per day if tolerated [40]. The decision of ICD implant 
in asymptomatic Brugada individuals needs true contemplation in view of the rarity 
of the events. Annual rate of cardiac events in this group is 0.5% versus 7.7%–10.2% 
in VF patients and 0.6%–1.2% in syncope patients [41]. Many authorities in the field 
do not recommend ICD implant in asymptomatic Brugada individuals [42]. With 
a history of VT/VF or arrhythmia-related syncope, in Brugada individuals, ICD 
must be the first-line management. In contrast to what we have mentioned earlier 
in LQTS management, tiered therapy is recommended in BrS ICD programming. 
Fractionated late potentials in the anterior aspect of right ventricular out flow tract 
(RVOT) were detected in nine patients with VF storm due to Brugada syndrome 
[43]. Ablation at this site normalized the Brugada ECG findings in majority of 
patients (with one patient only left with amiodarone) [44]. These electrocardio-
graphic findings and site ablation results were repeated in recent works [45, 46].
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2.3 Catecholaminergic PMVT risk stratification and management plan
Catecholaminergic polymorphic VT (CPVT) is a syndrome of exercise- or stress-
induced PMVT in the absence of overt structural heart disease or abnormalities on 
the baseline ECG. CPVT should be suspected in patients with exertional presyn-
cope/syncope and a normal resting QTc interval. The most useful diagnostic test is 
the stress ECG. The hallmark finding is exertional bidirectional VT, although more 
commonly exertional ventricular ectopy or short runs of PMVT may occur [47, 48]. 
The prevalence of CPVT is estimated to be 1 in 10,000, and it is often diagnosed 
among healthy children or young adults [49]. High doses (nadolol, 3–5 mg/kg) may 
be necessary to suppress exertional ectopy; doses can be titrated to effect based on 
inducibility of ventricular arrhythmias with stress testing [50]. Because of the high 
risk of recurrent events and SCD on β-blockers, adjunctive ICD implantation is 
recommended in all symptomatic patients.
Pharmaceutical emergency management involves intravenous beta blockers. 
Anesthetic measures to reduce adrenergic sympathetic surge like conscious sedation 
or even general anesthesia might be used in emergency situation especially with 
ICD shock storm. This approach still lacks scientific evidence. In spite of the pivotal 
role of beta blockers in CPVT management, recurrence of arrhythmic events is still 
high. Eleven studies have been reviewed comprising 493 patients, and 88% were on 
beta blockers, with follow-up periods of 20–96 months. The eight-year arrhythmic 
event rate was 37.2%, with a near-fatal event rate of 15.3% and a fatal event rate of 
6.4% [51]. This review alerts the arrhythmia community to very important manage-
ment alert, where suppression of arrhythmia induced by exercise with beta blockers 
does not imply long-term effectiveness.
If gene mutation is positive for CPVT, without using beta blockers, SCD may 
occur even if exercise test is negative [52]. Flecainide is also a promising first-line 
drug. It might be used as second-line treatment combined with beta blockers regard-
less of the presence or absence of genetic mutation [53, 54]. It was proved to target 
the calcium waves inducing arrhythmia as it targets RYR2 channels [55]. Flecainide 
was shown to be highly effective if combined with beta blockers compared to 
beta blockers alone (P < 0.003) [56]. The recommended daily dose of flecainide is 
150–200 mg with maximum dose not exceeding 300 mg/day. In genotype-negative 
CPVT patients, flecainide was shown to reduce VT during exercise test [57].
Surgical option represented by left cardiac sympathetic denervation (LCSD) is 
an effective choice as a hybrid therapy to pharmaceutical agents. It was found to be 
safe and effective and requires minimal endoscopic surgery, although its availability 
is a problem. LCSD was found to raise the VT threshold and ventricular refractori-
ness [58]. In high-risk patients, it might be advisable to be done early in the treat-
ment plan. Larger cohort studies are needed for better understanding the role of 
LCSD in PCVT [59].
ICD, with primary termination, was able to clear VT in 24 young patients with 
PCVT. In spite of its critical role in management, ICD may act as proarrhythmic 
due to its induction of adrenergic state [60]. In certain patients with cautious 
personalities, ICD may act paradoxically to increase arrhythmic events through 
emotionally higher adrenergic state of fear. This is why reducing negative emotions 
should be thought of as primary essential non-pharmaceutical measure to inhibit 
arrhythmic events in any adrenergic-mediated arrhythmia [61]. This should be 
emphasized more in younger age group and patients with higher shock frequency. 
It was found that patients younger than 50 years of age might be at higher risk due 
to life style disruption and distressing social comparisons [62]. Programming ICD 
in PCVT patients should be tiered therapy with three zones of management (SVT, 
VT and VF). This is important to avoid inappropriate shocks with its vicious cycle 
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arrhythmic effects. Symptomatic CPVT patients should avoid exercise. Guarded 
exercise might be allowed to asymptomatic CPVT individuals.
As we emphasized above, suppression of exercise-induced ventricular arrhythmias 
with β-blocker therapy does not necessarily translate into long-term effectiveness of 
therapy [63].
2.4  Early repolarization syndrome (ERS) risk stratification and management 
plan
This is a steep repolarization of transmural AP gradients that was thought to be 
benign and was proven to be truly arrhythmogenic in 2008 after Haïssaguerre et al.’s 
landmark study [64]. Because of their similar pathophysiological mechanisms, 
it is not surprising that the approach to therapy of ERS is similar to that of BrS. 
β-adrenergic activation with isoproterenol is effective in suppressing ER arrhyth-
mias by enhancing inward calcium current [65]. As cardiac transient outward 
potassium current (Ito) inhibitor, quinidine is also effective [66]. An observational 
cohort study of 122 patients (age 25–49, 90 male patients) with ERS who implanted 
ICD was done [67]. Follow-up was done through ICD interrogation. Successful sup-
pression of VF in this cohort was demonstrated using isoproterenol (100% success) 
in acute cases, while quinidine was shown superior in chronic cases. Quinidine was 
able to abolish all VF attacks over 2 years. Quinidine success was extraordinarily 
confirmed as it was able to restore normal ECG. To the surprise, medications like 
β-blockers, amiodarone, class 1C agents, mexiletine and verapamil were found not 
to be effective. In another publication of five BrS and two ERS patients, a combina-
tion of cilostazol and bepridil was found to suppress VF effectively [68]. Cilostazol 
inhibits the activity of phosphodiesterase III in the heart. It thereby increases the 
inward calcium current (ICa) via elevation of the intracellular concentrations of 
cyclic adenosine monophosphate (cyclic AMP), which shares some pharmacologi-
cal features with isoproterenol. Cilostazol can cause symptomatic palpitations and 
its long-term effects have not been reported. Bepridil (calcium antagonist with 
fast kinetic block of sodium currents) inhibits most types of potassium currents, 
including (Ito) and could decrease the number of sudden VF episodes in patients 
with idiopathic VF (including those with BrS). The addition of bepridil could 
attenuate cilostazol-induced palpitations without preventing the suppressive effects 
of cilostazol on VF [69].
If VT or VF is documented, then ICD is indicated. No available clinical strategy 
is present for asymptomatic individuals with ERS electrocardiographic manifesta-
tion. Syncope correlation to the arrhythmia in ESR is unusual. The presence of 
syncope in ERS-diagnosed individuals should warrant more investigations.
2.5 Idiopathic VF management plan
Although the exit list of primary arrhythmias from idiopathic VF circle is 
increasing, it still stands alone as a primary diagnosis. Acute suppression of the 
VF can be achieved successfully with isoproterenol or quinidine [70, 71]. The 
mechanism of quinidine effect in idiopathic VF is unknown [72]. The famous Ca++ 
channel blocker, verapamil, also proves to be successful acutely [73]. Ventricular 
ectopy mostly originating from the distal Purkinje system is observed in up to 30% 
of cases of idiopathic ventricular fibrillation VF [74].
Promising publications report the successful ablation of the triggering PVC with 
cure rate of 89% [75]. After ablation rate of recurrence is low (18%), there is a pos-
sibility that the recurrence is due to another site of triggering PVC [76]. For patients 
who were lucky to be retrieved after VF, ICD implant is a MUST.
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2.6  Progressive cardiac conduction disease (PCCD) and inherited sinus node 
dysfunction (SND) management plan
Both PCCD and SND contain channelopathy elements and overlap with chan-
nelopathy syndromes in some cases. Until the research in genetic engineering and 
tissue engineering reaches to revolutionary solutions for those two conductions, 
device therapy with pacemakers and ICDs will be the standard management. ICD 
(which carries pacer capabilities) will be the choice in rare cases of the overlap 
nature with other tachyarrhythmias. In this condition, hybrid pharmaceutical agent 
might be used.
3. Future speculations on the approach to channelopathy
The explosive medical informatics that we have obtained as human species 
about SCD in the last three decades are landmarks in human history. In addition to 
continuation of the gracious efforts in the arena of cardiovascular genetics, epi-
genetics and molecular genetics, it is always advisable to dive more into the microp-
erspective, as well as macroperspective. It is a way of interpreting facts with the 
true spectrum of the creature and biology from genes to galaxies. This is a visionary 
way of thinking that we and our team adopted since 2006 in the King of Organs 
series for advanced cardiac sciences conferences (2006, 2008, 2010, 2012 and 2019). 
Channelopathy and its related experimental research especially exploring the 
secrets of SCD are creating an ideal example of scientific incorporation of this new 
visionary understanding. Induced pluripotent stem cell–derived cardiomyocytes 
provide a new platform for studying arrhythmic disorders leading to sudden cardiac 
death. Cellular transfection models, which are the most commonly used cellular 
models, are able to mimic the expression of a single-ion channel. Both are amenable 
for the weak electromagnetic currents that are in common between genes and 
cosmos.
3.1 Future speculations in the genetic arena
Tremendous progress has been made in the discovery of putative mutations and 
genes responsible for different channelopathies. In the way of advances to scrutinize 
the pathogenic mutations comes the growing number of variants of unknown 
significance (VUS). It is an allele, or variant form of a gene, that has been identi-
fied through genetic testing but whose significance to the function or health of an 
organism is not identified. Researchers continue to work on better understanding 
how to stratify the risk of life-threatening arrhythmia based on the genotype and 
phenotype of the individual. Giustetto and his colleagues reported finding on  a 
study of 53 patients from the European Short QT Registry. They found that A 
familial or personal history of cardiac arrest was present in 89%. Sudden death was 
the clinical presentation in 32%. The average QTc was 314 ± 23 ms. A mutation in 
genes related to SQTS was found in 23% of the probands; most of them had a gain 
of function mutation in HERG (SQTS1). Almost 43(45%) of patients received an 
implantable cardioverter defibrillator, and 12(23%) patients received long-term 
prophylaxis with hydroquinidine. Patients with a HERG mutation had shorter 
QTc at baseline and a greater QTc prolongation after treatment with HQ. During 
follow-up, 2(4%) already symptomatic patients received appropriate implantable 
cardioverter defibrillator shocks and 1(2%) had syncope. The event rate was 4.9% 
per year in the patients without antiarrhythmic therapy. No arrhythmic events 
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occurred in patients receiving HQ [77]. The delta T50 is a measure of the variability 
of ventricular repolarization (at 50% of the T-wave downslope). It has been used to 
identify patients with LQTS in combination with QT interval cutoffs, as well as to 
identify patients at higher risk for cardiac events [78]. Rest and exercise QT interval 
measurements have been used to create a validated algorithm for diagnosing LQTS 
[79]. End-recovery QT interval measurements have also been used and, in combina-
tion with clinical history and mutation-specific information, can aid in understand-
ing the pathogenicity of VUS [80]. Copy number variations (CNV) are a form of 
genetic abnormality that may explain the genetic basis of channelopathies in cases 
where there is no identifiable point mutation [81]. It is conceivable that in the 
future CNV may be added to genetic screens. Despite our increasingly sophisticated 
knowledge of the underlying pathophysiology, novel medical therapies tailored spe-
cifically for these syndromes have yet emerged in the clinical setting. Novel forms of 
treatment that specifically address the aberrant molecular pathophysiology defining 
these conditions will be our immediate priority step in order to effectively suppress 
arrhythmic events and to ultimately obviate the need for ICD implants.
3.2  Decoding the channelopathies’ mysteries using induced pluripotent stem 
cell-derived cardiomyocyte research
The available platforms, shaping the future, to develop and investigate pharma-
ceutical therapeutic mechanisms for successful channelopathies treatment can be 
classified into different levels. First is at the organism level including clinical as well 
as animal models. Second is at the tissue and organ level (Purkinje fibers). Third is 
at cellular and molecular level (cardiac ions, induced pluripotent stem cells) [82]. 
Since the first report in 2006, bench researchers have made use of “induced pluripo-
tent stem cell” (iPS) systems to study the electrophysiological and pharmacological 
characteristics of cardiomyocyte cells that are specific to an individual patient and 
his/her mutation and channelopathy. This technology has huge potential to promote 
our understanding of individual channelopathies and further steer the management 
of channelopathies in an individualistic, genotype-specific manner in the future 
[83, 84]. It provides a robust platform to advance the science and clinical care of 
sudden cardiac death. Major ion channels of the human heart are expressed in the 
human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM). The 
iPSC-CMs are created by somatic cells reprogramming into pluripotent stem cells 
using viral transduction or non-viral transfection or soluble proteins to introduce 
transcriptional factors to the somatic cell [85]. The resulting induced pluripotent 
stem cell can be differentiated specifically to induced pluripotent stem cell-derived 
cardiomyocyte (iPSC-CM) [86]. The iPSC-CMs can express encoded genes of the 
heart that might be absent in the original donor somatic cell. An ion channel disease 
can be expressed and recapitulated electrophysiologically so clinical diagnosis can 
be identified as well as genetic screening in the family. Variant of uncertain signifi-
cance (VUS) can be developed where electrophysiological testing can be examined 
in the produced iPSC-CMs. Then comparison to the index case can be done. As the 
case in genetic testing, iPSC-CM may miss identifying the arrhythmia. In this situ-
ation, we will rely on clinical evaluation and family screening. Induced pluripotent 
stem of human cardiomyocyte (iPSC-CM) is superior to animal models or heterolo-
gous transfection models for channelopathies research (Figure 1) [87]. Its capabili-
ties to create specific therapeutic options and its abilities to define disease-specific 
drug toxicity are unique.
This level of research is expected to illuminate our understanding of the true 
pathophysiology of channelopathies and their targeted therapies.
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3.3 Fine-tuning the sympathovagal balance
Since the early 1990s, ICD have become a standard therapeutic option for VT/
VF in channelopathy subjects and in most of the times the first therapeutic choice 
to defibrillate the fatal rhythms. As time passed, we gained the knowledge of how to 
fine-tune our ICD subjects to minimize or abolish shocks without using medications 
as much as possible. Despite the effectiveness of the ICD in preventing sudden death, 
anxiety, depression and post-traumatic stress disorder (PTSD) plays a contributing 
role in the high 1-year mortality rate observed after ICD implantation. ICD patients 
are at higher risk of having arrhythmias and therefore of receiving shocks, because 
of their fear of receiving shocks. Negative emotions lead to an increased incidence of 
disorders in heart rhythms and in the autonomic nervous system functioning. On the 
other hand, the positive psychophysiological state, called heart coherence, is associ-
ated with high performance, stress reduction and greater emotional stability, and less 
arrhythmic events. Heart rate variability (HRV) is considered a measure of neuro-
cardiac function that reflects heart-brain interactions and autonomic nervous system 
(ANS) dynamics. HRV pattern with cardiac coherence (CC) is seen as sine wave 
highly regular pattern compared to the chaotic pattern seen with anger, frustration 
and other negative emotions. The HeartMath Institute (California, Boulder Creek) 
developed a heart rhythm monitoring and feedback system that enables physiologi-
cal coherence to be objectively monitored and quantified.
Training ICD patients’ to self-regulate emotions can produce broad improve-
ments in increasing or strengthening self-regulatory capacity, making them 
less vulnerable to depletions and fear of and consequently less rhythmic events. 
Resilience is defined by the HeartMath researchers as the capacity to prepare for, 
recover from and adapt in the face of stress, adversity, trauma or challenge. It 
reflects the state of sympathovagal balance where the ion travel across the cellular 
membrane channels is in true physiological homeostasis. Teaching how to improve 
self-resilience is especially important for highly potential subjects for PTSD like 
ICD patients. In view of the role of the effects of negative emotions on induction 
Figure 1. 
Potential role for iPSC-CMs in the evaluation of patients with known or at risk for arrhythmic disorders. 
Clinical genetic testing attempts to identify a rare variant in genes commonly associated with arrhythmic 
disorders. (illustration credit: Ben smith) [87].
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of T-wave alternans (TWA) and repolarization instability and its relation to future 
ventricular arrhythmias in patients with ICDs, we postulate that teaching the 
importance of positive emotional states and building a heart coherent pattern are 
excellent life choices that can interrupt the negative emotion, fatal rhythm and 
shock continuum for ICD patients [88, 89].
3.4  Earth geomagnetic activity orchestrating autonomic nervous system, 
arrhythmogenesis and SCD
New perspective is evident disclosing the scientific background of historical 
and philosophical dilemmas. The human heart rate variability as a measure of the 
autonomic nervous system (ANS) functions is in delicate resonance with planetary 
magnetic field. Statistically significant correlations have been established linking 
earth’s magnetic activity to psychophysiological well-being including arrhythmias 
and sudden cardiac death. Different pathomechanisms are operating through which 
ANS induces the fatal heart rhythms. Andrew Armor, the pioneer of neurocardiol-
ogy, elaborates in this direction as well as heart brain communications [90]. The 
state of cardiac coherence (CC) where HRV-dominant frequency peak is in the 
0.04–0.26 Hz range and more peculiarly around 0.1 Hz carries the secrets of psycho-
physiological well-being and planetary resonance [91–93]. Daily autonomic nervous 
system activity not only responds to changes in solar and geomagnetic activity 
(SGMA), but it is also synchronized with the time-varying magnetic fields associ-
ated with geomagnetic field-line resonances and Schumann resonances [94, 95]. The 
great planetary frequency around 0.1 Hz acts also indirectly toward normal heart 
rhythm by reducing systemic blood pressure in hypertensive subjects [96, 97]. SCD 
and cerebral strokes and increase in emergency calls were linked to periods of geo-
magnetic disturbances (low level) and higher level of cosmic rays. This is suggesting 
biophysical cause effect relationship between cosmic rays and medical events of 
elderly humans [98, 99]. Daily autonomic nervous system activity not only responds 
to changes in solar and geomagnetic activity, but it is also synchronized with the 
time-varying magnetic fields associated with geomagnetic field-line resonances and 
Schumann resonances [100].
In this direction, the longest record of human heart activity synchronized to 
solar wind indices as well as Schumann resonances and the cosmic rays has been 
done by our group. A total of 97,000 hours of records were managed statistically. 
We have satisfying scientific evidence illustrating daily changes of the ANS in 
response to solar as well as geomagnetic activity. Those ANS responses are initiated 
after different times of the changes of the solar and planetary activities and when 
it occurs and it persists for varying times. Increasing heart rate was correlated 
to increase in solar wind intensity. This is explained as biological stress response 
of solar winds on human heart through sophisticated mechanisms. The rise of 
Schumann resonance power, solar radio flux and cosmic rays are all reflected in the 
increase of parasympathetic tone and HRV. The degree of effect of those energetic 
environmental stressors on human cardiovascular system affects different people 
differently depending on their health, sensitivity and self-regulation capabilities 
[101]. The scientific community in the field is active to establish the effect of SGMA 
on heart rhythm at cellular level. Laboratory findings demonstrate the effect of 
ion cyclotron mechanism on extracted myocardial cell regulation [102]. It seems 
that Schumann resonance is a major interlayer in the SGMA effect on ion chan-
nels and the ion transport in cardiac cells and accordingly in the susceptibility of 
channelopathic subjects to the fatal rhythms. The influence of extremely weak 
magnetic field in the Schumann resonances (ScR) on the creatine kinase (CK) 
release, calcium transients as well as spontaneous contractions of rat cardiac cell 
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cultures was examined. The application of 7.8 Hz, magnetic field of 90 nT was 
associated with gradual reduction in the spontaneous Ca++ transient amplitude. 
After 40 minutes of magnetic field application, 28% of the initial amplitude was 
reached. This reduction was associated with the calcium transient time gradually 
reduced. The effect is frequency dependent. The described changes occurred only 
in the 7.6–8 Hz. The frequency of 7.8 Hz is frequency of both central nervous system 
and cardiovascular system. It is the basic frequency responsible for the resonance 
between us humans as well as the biology on one hand and the cosmic environment 
on the other hand. The application of 7.8 Hz, magnetic field of 90 nT for 90 minutes 
results in the reduction of creatine kinase (CK) release to the buffer. This result was 
obtained during normal conditions, hypoxic environment and use of 80 μM H2O2 to 
induce oxidative stress. It sees that the first range of ScR has an effect on cardiac cell 
characterized by CK release reduction as a stress response and this effect is of a pro-
tective effect [103]. Magnetic field dynamics could add to our future understand-
ing of the SGMA interaction with human heart in health and disease. The known 
transmembrane pacemaker protein CHN4, present in both sinoatrial and AV nodal 
cells, could interact with field information to provide specificity in an electronic 
key-to-lock mechanism interaction [104]. It is conspicuous that the near future is 
carrying more details to disclose the true pathomechanism of how modulation of 
HRV with fluctuation of SGMA can trigger the fatal rhythms and sudden death. 
More intelligent preventive as well as therapeutic strategies will be then available.
4. Summary
Risk stratification for LQTSs is available with high correlation to positive genetic 
testing with 75% likelihood if the score is more than 4 points. Half of LQTS cases 
prove positive mutation. This is not the case with other channelopathies where 
paucity of positive mutations is the role. Beta blockers (propranolol and nadolol 
than metoprolol) are the first-line and easiest therapeutic choice for both LQT1 
and LQT2. There is no scientific evidence favoring selective over non-selective beta 
blockers. It is always advised to keep beta blockers as adjunct treatment after ICD 
implants. In the current medical literature, there is controversy regarding the use 
of beta blockers in LQT3. Scientific evidence is suggesting significant therapeutic 
role of sodium channel blockers like ranolazine, mexiletine and flecainide in LQT3 
treatment. Mexiletine was proved also of being an effective therapeutic option in 
LQT3 as well as LQT1 and LQT2. In the absence of concomitant gene mutations, 
epinephrine and isoproterenol were found to be effective in acquired LQTS. The 
implantation of an ICD is pivotal secondary prevention in LQTS and a reasonable 
primary prevention approach in selected cases. Surgical therapy in the form of left 
cardiac sympathetic denervation (LCSD) is a well-accepted treatment option in 
LQTS patients. It is an option in selected cases like LQT1 and LQT2 patients with 
no proper response to beta blockers, intolerance to beta blockers, or after ICD 
implant with recurrent arrhythmias. Aggressive management of febrile illnesses as 
well as avoidance of drugs inducing VT/VF is critical in BrS arrhythmia patients. 
Isoproterenol intravenously is used with success to control VF storms in BrS. ICD 
implant is a must for secondary prevention but is guarded in primary prevention 
especially in asymptomatic individuals. In case of frequent ICD shocks, quinidine 
can be used as adjunct treatment (up to 600 mg a day). Ablation of the anterior 
aspect of RVOT seems a promising and successful option in BrS patients. In PCVT, 
high doses of nadolol (3–5 mg/kg) may be necessary to suppress exertional ectopy. 
Because of the high risk of recurrent events and SCD on β-blockers, adjunctive ICD 
implantation is recommended in all PCVT symptomatic patients. Physicians must 
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never rely on exercise test result for PCVT management. Flecainide (150–200 mg a 
day) is a promising first-line drug or as adjunct with beta blockers. Surgical option 
for PCVT represented by LCSD is an effective choice as a hybrid therapy to pharma-
ceutical agents. ICD, with primary termination, is the golden choice. Due to the role 
of emotional upset to induce attacks of VT/VF in PCVT, emotional management 
is of paramount importance. ER pattern was proven to be truly arrhythmogenic in 
2008. Pathophysiological mechanism, as well as therapeutic approaches of ERS, is 
similar to that of BrS. Enhancing inward calcium current with β-adrenergic activa-
tion using isoproterenol is effective in suppressing ER arrhythmias in acute cases. 
Inhibiting cardiac transient outward potassium current (Ito) using quinidine is 
also effective to suppress ER arrhythmias and was of proven superiority in chronic 
cases. A combination of cilostazol and bepridil was found to suppress VF in ERS 
and BrS effectively. In idiopathic VF (IVF) secondary prevention; immediate ICD 
implantation is a must. Acute suppression of the VF can be achieved successfully 
with isoproterenol or quinidine. Verapamil was found to be also successful acutely. 
Ablation of the triggering PVC seems to be a very promising choice. For PCCD and 
SND with channelopathy elements, ICD with pacemaker capabilities is the standard 
choice. Toward the discovery of putative mutations and genes comes variants of 
unknown significance (VUS) (looking for functional significance of allele or gene 
variant). The delta T50 (a measure of the variability of ventricular repolarization at 
50% of the T-wave downslope) is a new tool to improve our diagnostic accuracy of 
channelopathies. In the absence of identifiable point mutation, copy number varia-
tion (CNV) is a form of genetic abnormality, which may explain the genetic basis 
of channelopathies. The psychophysiological well-being associated with positive 
emotional state orchestrates the sympathovagal tone favorably. Cardiac coherence 
(CC) (where heart frequencies dominate in the range of 0.04–0.26 Hz) is a state of 
recruiting positive emotion by special training resulting in homogeneity between 
all body functions and systems. It is seen as sine wave appearance of HRV. Training 
ICD patients to self-regulate emotions with cardiac coherence can increase self-
regulatory capacity, making them less vulnerable to depletions and fear of and 
consequently less rhythmic events. In view of the complexity of the different 
channelopathies and its variable responses to different treatment modalities, it is 
believed that comprehensive global perspective is highly needed. We adopted new 
universal perspective for diseases management extending from genes to galaxies. 
Experimental research on channelopathies is a model in this direction. Induced 
pluripotent stem cell–derived cardiomyocytes provide a new platform for studying 
arrhythmic disorders leading to sudden cardiac death. Cellular transfection models 
are able to mimic the expression of a single-ion channel. Both are amenable for the 
weak electromagnetic currents that are common between genes and cosmos. The 
rise of Schumann resonance power, solar radio flux and cosmic rays are all reflected 
in the increase of parasympathetic tone and HRV. The degree of effect of those 
energetic environmental stressors on human cardiovascular system affects differ-
ent people differently depending on their health, sensitivity and self-regulation 
capabilities. The protective effect of simulated weak magnetic field in the range of 
the first Schumann resonance (7.8 Hz) is proven at cellular level. The future in this 
direction is promising to revolutionize our interventional capabilities to treat and 
prevent channelopathies in the human kind.
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Appendices and nomenclature
BrS Brugada syndrome
CC cardiac coherence
CPVT catecholaminergic polymorphic ventricular tachycardia
ERS early repolarization syndrome
HRV heart rate variability
LQTS long QT syndrome
PCCD progressive cardiac conduction disease
SCD sudden cardiac death
ScR Schumann resonance
SGMA solar geomagnetic activity
SNP single-nucleotide polymorphism
SQTS short-QT syndrome
VF ventricular fibrillation
VT ventricular tachycardia
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